Impact of renal dysfunction on clinical outcome in patients with low risk of atrial fibrillation

Circulation Journal

Volumn 78, Issue 4, 2014, Pages 853-858

  Lin, Wen Yu ^a   Lin, Yenn Jiang ^b,c   Chung, Fa Po ^b,c   Chao, Tze Fan ^b,c   Liao, Jo Nan ^b,c   Chang, Shih Lin ^b,c   Lo, Li Wei ^b,c   Hu, Yu Feng ^b,c   Chiang, Chern En ^b,c   Cheng, Shu Meng ^a   Lin, Wei Shiang ^a   Chen, Shih Ann ^b,c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anticoagulation; Atrial fibrillation; Mortality; Renal dysfunction; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; FLECAINIDE; PROPAFENONE;

ADULT; AGED; ARTERY EMBOLISM; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; EVALUATION AND FOLLOW UP; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; SCORING SYSTEM; SEVERE RENAL IMPAIRMENT; VERY ELDERLY;

ADULT; ATRIAL FIBRILLATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 84897847538     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.cj-13-1246     Document Type: Article

References (32)

1. The task force for the management of atrial fbrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fbrillation. Eur Heart J 2010; 21: 2369-2429.
2. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fbrillation: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 2011; 123: 2946-2953.
3. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for geographic and racial differences in stroke (REGARDS) study. Circ Arrhythm Electrophysi-ol 2011; 4: 26-32.
4. Sandhu RK, Kurth T, Conen D, Cook NR, Ridker PM, Alber CM. Relation of renal function to risk for incident atrial fbrillation in women. Am J Cardiol 2012; 109: 538-542.
5. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular fltration rate on risk of thromboembolism in atrial fbrillation: The anticoagu-lation and risk factors in atrial fbrillation (ATRIA) study. Circulation 2009; 119: 1363-1369.
6. Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, et al. Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonval-vular atrial fbrillation. Am J Cardiol 2011; 107: 912-916.
7. Olesen JB, Lip GYH, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fbrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-635.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular fltration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-470.
9. Lu TH, Lee MC, Chou MC. Accuracy of cause of death coding in Taiwan: Types of miscoding and effects on mortality statistics. Int J Epidemiol 2000; 29: 336-343.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospi-talization. N Engl J Med 2004; 351: 1296-1305.
11. Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, et al. Associations between renal function, atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fbril-lation. Circ J 2011; 75: 2326-2332.
12. Chao TF, Tsao HM, Ambrose K, Lin YJ, Lin WS, Chang SL, et al. Renal dysfunction and the risk of thromboembolic events in patients with atrial fbrillation after catheter ablation. The potential role beyond the CHA2DS2-VASc score. Heart Rhythm 2012; 9: 1755-1760.
13. Wójcik M, Erkapic D, Berkowitsch A, Zaltsberg S, Greiss H, Schmitt J, et al. Ipsilateral circumferential radiofrequency ablation of atrial fbrillation with irrigated tip catheter: Long-term outcome and pre-procedural predictors. Circ J 2013; 77: 2280-2287.
14. Wójcik M, Berkowitsch A, Greiss H, Zaltsberg S, Pajitnev D, Deubner N, et al. Repeated catheter ablation of atrial fbrillation: How to predict outcome? Circ J 2013; 77: 2271-2279.
15. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fbrillation: Implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
16. Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA, et al. The prevalence of and factors associated with chronic atrial fbrillation in medicare/medicaid-eligible dialysis patients. Kidney Int 2012; 81: 469-476.
17. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, et al. Prevalence of atrial fbrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46: 897-902.
18. Chua SK, Shyu KG, Lu MJ, Hung HF, Cheng JJ, Lee SH, et al. Association between renal function, diastolic dysfunction, and postoperative atrial fbrillation following cardiac surgery. Circ J 2013; 77: 2303-2310.
19. Hsiao SH, Chiou KR. Left atrial expansion index predicts atrial f-brillation in dyspnea. Circ J 2013; 77: 2712-2721.
20. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, Castellano P, Garcia-Cortes MJ, Liebana A, et al. Atrial fbrillation in incident dialysis patients. Kidney Int 2009; 76: 324-330.
21. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, et al. Infuence of atrial fbrillation on the morbidity and mortality of patients on hemodialysis. Am Heart J 2000; 140: 886-890.
22. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in atrial fbrillation patients: The Euro Heart Survey. Chest 2010; 138: 1093-1110.
23. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, et al. Dilemmas in the management of atrial fbrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711.
24. Yang F, Chou D, Schweitzer P, Hanon S. Warfarin in hemodialysis patients with atrial fbrillation: What beneft? Europace 2010; 12: 1666-1672.
25. To AC, Yehia M, Collins JF. Atrial fbrillation in hemodialysis patients: Do the guidelines for anticoagulation apply? Nephrology 2007; 12: 441-447.
26. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fbrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
27. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fbrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2599-2604.
28. Connoly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fbrillation. N Engl J Med 2009; 361: 1139-1151.
29. Patel RR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Ribaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med 2011; 365: 883-891.
30. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial f-brillation. N Engl J Med 2011; 365: 981-992.
31. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S; J-ROCKET AF study investigators. Safety and effcacy of adjusted dose of rivaroxaban in Japanese patients with nonvalvular atrial fbrillation: Subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013; 77: 632-638.
32. Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, et al. Betrixaban compared with warfarin in patients with atrial fbrillation: Results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013; 34: 1498-1505.